TECHNICAL ANALYSIS

[$Pistol Pete$]

$PMCB Ifosfamide in its active form is usually delivered intravenously and then activated in the liver. The process "works", but much of the drug doesn't make it to the pancreas. To deliver a dose big enough to make a dent in a pancreatic tumor, nasty side effects are almost a given. The Cell-in-a-Box approach circumvents this inefficient form of delivery by inserting encapsulated P450-producing cells very near the tumor itself, which means ifosfamide isn't activated until it's at or near the pancreatic tumor, which means the bulk of the drug is delivered where it needs to be delivered. This in turn means less of the drug is necessary to produce a response. Less of a drug means fewer side effects, without giving up efficacy.

Go $PMCB